MicroPort NeuroTech and AOI Tech Announce Strategic Partnership to Accelerate BCI-Exoskeleton Integration and Industrial Ecosystem Development

2026Year5Month28Recently, MicroPort NeuroTech Corporation (hereinafter referred to as "MicroPort NeuroTech™") officially signed a strategic cooperation agreement with OYMotion Technology Co., Ltd (hereinafter referred to as "OYMotion"),Both parties will focus on brain-computer interfaces.-Deeply integrate with exoskeleton robotic systems, conduct long-term R&D and application scenario exploration, and jointly advance the clinical application and industrialization of cutting-edge brain science technologies.

2024In [Year], MicroPort NeuroVascular, a wholly-owned subsidiary of MicroPort NeuroTech, together with the Shenzhen Guidance Fund, CICC Capital, and other parties, jointly initiated and established a fund with a total scale of10hundred million-yuan CICC Brain Science Fund. This fund is Shenzhen's "20+8”In the industrial cluster strategyOnly100%Specialized Fund Focused on Brain Science and Brain-Inspired Intelligence Industries，This indicates that MicroPort NeuroTech had already completed the top-level strategic design for industrial capital earlier—making substantial capital investments to "pave the way" for the brain-computer interface (BCI) sector.

2025Year11`Month`20Recently, MicroPort NeuroTech™ held the unveiling ceremony for the Chaos Brain-Computer Interface Research Institute., employing professionals with over15years of experience in the research and development of implantable medical devicesWill ZhangDr. [Name] serves as Chief Researcher, officially launching a strategic push into the cutting-edge field of brain-computer interfaces (BCI). The Research Institute will function as an internal innovation engine, continuously advancing the R&D of BCI hardware systems, software algorithm design, and key breakthroughs in electrode technology, thereby establishing a technical platform to explore solutions for neurological diseases.

Less than seven months, MicroPort NeuroTech™ has signed a strategic cooperation agreement with OYMotion, entering the advanced stage of brain-computer interface (BCI) applications. The greatest value of this partnership lies in the highly complementary and precisely integrated capabilities of both parties, establishing a highly rare and complete technological closed-loop that seamlessly connects the entire pipeline from "decoding the brain" to "driving robots."

MicroPort NeuroTech™As a pioneer in China’s neurointerventional medical device industry and currently the largest domestic brand, the company has established a formidable technological barrier in device R&D, clinical translation, and commercialization strategy. Having deeply cultivated the neurointerventional sector for years, it boasts the most comprehensive product portfolio among domestic enterprises,2025 For years, its domestic market share has consistently ranked first among domestically produced brands in China. The clinical resources, regulatory registration experience, and medical device R&D capabilities accumulated through sustained focus on the healthcare sector serve as the core foundation enabling brain-computer interfaces to transition from the laboratory to clinical applications.

OYMotion is a representative enterprise in China's non-invasive brain-computer interface sector, deeply engaged in brain/Electromyographic and neural signal acquisition、AISpecializing in the R&D of motor intention decoding and multi-degree-of-freedom robotics, the company maintains a mature product portfolio encompassing bionic and dexterous hands. With in-house manufacturing capabilities for core components, it has accumulated extensive industrialization experience in the field of rehabilitation engineering.

In this collaboration, both parties will establish a comprehensive, multi-dimensional, long-term, and stable partnership to jointly explore innovative applications of brain-computer interface (BCI) technology in medical rehabilitation, human-computer interaction, and other related fields. MicroPort NeuroTech™ will focus on leveraging its advantages in neurotechnology R&D, clinical translation, and commercialization strategy; OYMotion will provide high-performance, highly adaptable exoskeleton robotic devices and intelligent control solutions.

Following the collaboration between the two parties, it formed“Brain signal acquisition → intent decoding → robotic execution” complete technological closed-loop.Looking at both domestic and international markets, there is virtually no single company capable of covering all three segments simultaneously. The collaboration between MicroPort NeuroTech™ and OYMotion currently represents the industry's closest solution to this goal.

Currently, as a strategic high ground in global technological competition, brain-computer interfaces (BCIs) are at a critical transitional phase from laboratory research to clinical application. Medical rehabilitation stands as the most mature sector for their commercialization, while the integration of BCIs with robotic exoskeletons represents a core direction for addressing motor dysfunction in patients with stroke, spinal cord injury, and related conditions. Traditional rehabilitation methods primarily rely on passive training, which typically yield limited efficacy and require prolonged treatment cycles. In contrast, BCI-driven active rehabilitation technology enables patients to...“Mind-controlled” limb movement enables active participation in rehabilitation, with clinical efficacy significantly improved compared to conventional methods. From the outset, this collaboration has been precisely anchored to the most critical clinical needs.

Phase 1: Active Rehabilitation for Patients with Nerve Injuries—— Surge in essential demand.Stroke is one of the diseases with the highest disability rate in China,The number of existing stroke patients in China is approximately1500Wanzhi1800ten thousand people, with over ... new cases annually400Tens of thousands, postoperative rehabilitation is an essential necessity., and active rehabilitation following stroke surgery is precisely one of the primary application scenarios for brain-computer interfaces.

Phase II: Dual Expansion of Technical Pathways and Indications——Explosive incremental growth.While further consolidating its core competencies in interventional technologies, the company is simultaneously advancing parallel R&D across multiple technological pathways to address the differentiated requirements of diverse medical scenarios. Addressing major medical challenges of significant public health impact, such as psychiatric disorders,The company adheres to the R&D philosophy of "condition-specific strategies", leveraging the synergistic complementarity of multiple technical approaches, including interventional, invasive, and semi-invasive modalities., providing patients with optimal medical solutions.

Phase 3: Human-Machine Interaction——Explosive growth in application scenarios.In the future, this technology platform can also be seamlessly expanded into the broader pan-AI field of human-machine interaction, breaking the physical limitations of traditional interaction to build a complete industrial ecosystem spanning from clinical healthcare to more diversified applications.

From the perspective of industry development prospects, on the policy front, China continues to step up support for the rehabilitation healthcare sector, with brain-computer interfaces and rehabilitation robots designated as key supported areas and approval processes accelerated; technologically,AI Algorithm iteration, electrode material innovation, and enhanced sensor precision are driving continuous optimization of product performance and gradual cost reduction; on the demand side, an accelerating aging population and heightened patient awareness of rehabilitation are fueling sustained essential demand in the medical sector, while consumer-side demand is gradually awakening. Industry forecasts predict that the global brain-computer interface (BCI)-integrated exoskeleton market will continue to expand, with China poised to become the world's largest single market.

# Review of MicroPort NeuroTech™The strategic evolution over the past two years clearly reveals a full-cycle ecosystem expansion pathway from diagnosis and treatment to neurological function reconstruction:

• Neurointervention:Has established a stable revenue and profit base, providing cash flow support for emerging businesses. Adjusted net profit at2020aged2025achieve approximately within the six-year period42.6%... compound annual growth rate, operational cash generation capability remains sustained.

• Neurosurgery:The entry of the "Wenqu™" hematoma aspiration device into the Special Approval Procedure for Innovative Medical Devices marks the company's expansion from cerebrovascular diseases to a broader range of neurosurgical conditions (including intracerebral hematoma, hydrocephalus, brain tumors, etc.). The product remains in the approval stage and has not yet contributed to revenue.

• Brain-Computer Interface:The Chaos Brain-Computer Interface Research Institute has been established to build a technological platform dedicated to exploring solutions for neurological diseases, offering new treatment options for patients with stroke, psychiatric disorders, and related conditions. This strategic partnership with OYMotion marks a key industrial collaboration for MicroPort NeuroTech™ in the brain-computer interface field.

MicroPort NeuroTech™Anchored in the high-demand neuro-medical sector and leveraging a full-chain technological closed-loop, through technical synergy with OYMotion, the company is steadily advancing the industrialization and clinical deployment of brain-computer interfaces (BCIs). The company’s strategic value lies not only in the breakthroughs already achieved, but also in its pioneering forward-looking strategic positioning and substantial resource allocation. Should technical validation proceed smoothly and clinical pathways be successfully established, MicroPort NeuroTech™ is poised to secure a pivotal role in the medical integration of BCI technology. It will not only provide novel treatment options for patients with stroke and psychiatric disorders, but also propel China’s BCI technology to leap from scientific breakthroughs to industry leadership, bringing renewed hope to patients with neurological injuries worldwide.